+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Brain Cancer Diagnostics Market by Technology, Product, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011103
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Cancer Diagnostics Market grew from USD 4.52 billion in 2024 to USD 5.11 billion in 2025. It is expected to continue growing at a CAGR of 12.48%, reaching USD 9.15 billion by 2030.

Navigating the Complex Terrain of Brain Cancer Diagnostics

The realm of brain cancer diagnostics sits at the intersection of cutting-edge science and urgent patient needs. Accurate and timely detection of malignancies such as glioblastoma and meningioma can mean the difference between life and loss. Advances in imaging, molecular tools, and pathology have redefined what clinicians can achieve in both early diagnosis and treatment planning. Yet this progress unfolds against a backdrop of complex reimbursement landscapes, evolving regulatory frameworks, and fierce competition among technology providers.

Decision-makers in hospitals, laboratories, and research institutes require a clear understanding of the innovations driving the market and the challenges that impede widespread adoption. Stakeholders must navigate a diverse ecosystem of genetic testing platforms, next-generation sequencing protocols, and high-resolution imaging modalities, while also contending with varying regional dynamics and trade policy pressures. By exploring the current landscape of brain cancer diagnostics, this executive summary aims to provide a cohesive narrative that illuminates critical trends, competitive forces, and opportunities for growth.

Innovations Redefining Brain Cancer Detection and Care

The next wave of breakthroughs in brain cancer detection is characterized by the convergence of artificial intelligence, precision medicine, and novel imaging modalities. Machine-learning algorithms are now capable of automating lesion segmentation on MRI scans with unprecedented accuracy, reducing both analysis time and inter-reader variability. Meanwhile, liquid biopsy approaches harness circulating tumor DNA to offer minimally invasive monitoring of disease progression and therapeutic response.

Molecular diagnostics have also undergone a transformative shift. Next-generation sequencing panels tailored to brain tumor genomics are enabling clinicians to identify actionable mutations in genes like IDH1 and FGFR, paving the way for targeted treatments. At the same time, digital pathology platforms are integrating image analysis tools that quantify histopathological markers, driving standardization across laboratories. These advancements are not isolated; rather, they form an interconnected ecosystem that empowers personalized care pathways and redefines how patients and providers approach brain cancer management.

How 2025 U.S. Tariffs Are Reshaping Brain Cancer Diagnostic Costs

The imposition of new U.S. tariffs in 2025 has introduced heightened cost pressures across the supply chain for diagnostic equipment, reagents, and consumables. Imports of high-end imaging systems and specialized laboratory instruments now incur additional levies, directly affecting the pricing strategies of global manufacturers. Organizations reliant on offshore production for diagnostic kits and reagents have faced either increased expenditure or the necessity of absorbing margin erosions.

In response, several market leaders have reevaluated their sourcing models, exploring regional manufacturing hubs to mitigate tariff impacts while maintaining supply continuity. Simultaneously, end users are renegotiating service contracts to secure more transparent cost structures for maintenance and training. Although these adjustments entail short-term investment, the resulting diversification of procurement channels is strengthening resilience against future policy shifts. As stakeholders adapt, the market is entering a phase in which agility and strategic sourcing will determine long-term competitiveness.

Unveiling Critical Segmentation Dynamics in Diagnostics

A comprehensive segmentation analysis reveals distinct dynamics across multiple axes of the diagnostics landscape. When examining technologies, genetic testing is gaining traction for hereditary predisposition screening, while imaging modalities such as CT scans, MRI, and PET are essential for anatomical and functional lesion characterization. Molecular diagnostics, including next-generation sequencing and polymerase chain reaction techniques, provide deep genomic insights, and pathology services spanning biopsy analysis and digital histopathology remain the reference standard for tumor confirmation.

Dividing the market by product category underscores the importance of consumables and reagents, notably diagnostic kits and specialized probes, which drive recurring revenue streams. Equipment investments focus on diagnostic systems, advanced imaging platforms, and lab instruments that facilitate automation and throughput. Service offerings, including preventive maintenance and comprehensive training programs, are critical for ensuring operational uptime and technical proficiency.

From an indication standpoint, glioblastoma multiforme dominates research funding due to its aggressive nature, while astrocytoma, meningioma, and oligodendroglioma each present unique diagnostic challenges and market opportunities. Distribution channels split between traditional offline sales through established distributors and emerging online platforms that offer streamlined ordering and rapid delivery. Lastly, end users such as diagnostic laboratories, hospital networks, and academic research institutes dictate product specifications and adoption timelines based on their clinical and operational requirements.

Regional Market Drivers and Divergences Across Global Hubs

Distinct regional characteristics are shaping the global market trajectory. In the Americas, robust investment in precision oncology and widespread access to advanced imaging infrastructure enable rapid uptake of next-generation diagnostic solutions. Regulatory agencies in North America have streamlined approval processes for companion diagnostics, fueling growth in targeted assay development and commercialization.

Across Europe, the Middle East, and Africa, a heterogeneous regulatory environment coexists with significant R&D clusters in Western Europe. Collaborative multicenter trials and pan-regional reimbursement initiatives are accelerating the adoption of digital pathology and molecular testing. In many emerging markets, cost containment measures and local manufacturing partnerships are vital for broadening access.

Asia-Pacific stands out for its expansive population base and escalating healthcare expenditures. Government-led precision medicine programs in China, Japan, and South Korea are propelling demand for integrated diagnostic workflows. At the same time, investments in telepathology and mobile imaging units are addressing diagnostic gaps in rural and underserved regions.

Strategic Moves of Leading Diagnostics Companies

Several industry leaders are steering the evolution of brain cancer diagnostics through targeted investments and strategic alliances. Global imaging titans have introduced high-field MRI systems equipped with advanced spectroscopy and real-time lesion tracking capabilities. Molecular diagnostics specialists have expanded their test menus to include multigene panels that detect rare and actionable variants specific to central nervous system tumors.

Partnerships between pathology software vendors and artificial intelligence developers are yielding digital platforms that automate stain quantification and prognostic scoring, reducing subjectivity. Meanwhile, emerging players are carving niches by offering rapid sequencing services and bespoke bioinformatics pipelines. Such collaborations underscore a broader trend: the convergence of hardware, software, and data analytics into unified diagnostic ecosystems. These integrated solutions aim to enhance diagnostic accuracy, shorten turnaround times, and support personalized treatment strategies.

Strategic Pathways for Industry Leadership in Brain Cancer Diagnostics

Industry leaders should prioritize diversification of manufacturing and sourcing strategies to mitigate policy-driven cost fluctuations. Establishing regional production hubs for reagents and kits will not only reduce tariff exposure but also improve supply chain transparency. Simultaneously, accelerating digital transformation initiatives-such as implementing cloud-based imaging archives and AI-driven pathology workflows-can optimize operational efficiency and reduce diagnostic bottlenecks.

Engagement with regulatory bodies is crucial to streamline approval pathways for novel diagnostics. By participating in harmonization efforts and real-world evidence programs, companies can expedite market entry and secure favorable reimbursement. Cross-sector collaborations, particularly between genomic testing firms and pharmaceutical developers, will generate companion diagnostics that tie directly into targeted therapies. Finally, investing in comprehensive training programs and strategic advisory services will enhance end-user proficiency and foster long-term partnerships.

Robust Methodological Framework Underpinning the Analysis

This analysis is grounded in a robust methodological framework combining primary and secondary research. Extensive interviews were conducted with senior executives from diagnostic laboratories, hospital networks, regulatory agencies, and research institutions to capture firsthand perspectives on market dynamics. Complementary secondary research encompassed peer-reviewed journals, company filings, and industry white papers to validate emerging trends.

Data triangulation ensured consistency across diverse sources, while an expert panel review provided critical feedback on preliminary findings. Quantitative data was standardized to reconcile discrepancies in reporting methodologies, ensuring reliable cross-comparisons. Rigorous quality control measures, including double data entry checks and methodological audits, underpin the credibility of the insights presented herein.

Concluding Observations on the Evolving Diagnostics Landscape

The evolution of brain cancer diagnostics is driven by technological innovation, evolving policy landscapes, and the imperative for personalized medicine. As imaging modalities become more sophisticated and molecular assays deliver deeper genomic resolution, stakeholders must remain agile to harness these advancements. Tariff-related cost pressures underscore the need for strategic sourcing and regionalized production, while segmentation and regional insights reveal nuanced opportunities across technology, product, and end-user domains.

Key players are forging integrated solutions that combine hardware, software, and data analytics to streamline workflows and support precision care. The market’s trajectory will hinge on collaborative efforts between industry, academia, and regulatory bodies, as well as on the ability of organizations to anticipate and adapt to shifting reimbursement and trade frameworks. By internalizing these trends, decision-makers can position themselves at the forefront of a rapidly changing diagnostic landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Genetic Testing
    • Imaging
      • Ct
      • MRI
      • PET
    • Molecular Diagnostics
      • NGS
      • PCR
    • Pathology
      • Biopsy Analysis
      • Histopathology
  • Product
    • Consumables & Reagents
      • Kits
      • Probes & Reagents
    • Equipment
      • Diagnostic Systems
      • Imaging Systems
      • Lab Instruments
    • Services
      • Maintenance
      • Training & Support
  • Indication
    • Astrocytoma
    • Glioblastoma Multiforme
    • Meningioma
    • Oligodendroglioma
  • Distribution Channel
    • Offline
    • Online
  • End User
    • Diagnostic Laboratories
    • Hospitals
    • Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • General Electric Company
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain Cancer Diagnostics Market, by Technology
8.1. Introduction
8.2. Genetic Testing
8.3. Imaging
8.3.1. Ct
8.3.2. MRI
8.3.3. PET
8.4. Molecular Diagnostics
8.4.1. NGS
8.4.2. PCR
8.5. Pathology
8.5.1. Biopsy Analysis
8.5.2. Histopathology
9. Brain Cancer Diagnostics Market, by Product
9.1. Introduction
9.2. Consumables & Reagents
9.2.1. Kits
9.2.2. Probes & Reagents
9.3. Equipment
9.3.1. Diagnostic Systems
9.3.2. Imaging Systems
9.3.3. Lab Instruments
9.4. Services
9.4.1. Maintenance
9.4.2. Training & Support
10. Brain Cancer Diagnostics Market, by Indication
10.1. Introduction
10.2. Astrocytoma
10.3. Glioblastoma Multiforme
10.4. Meningioma
10.5. Oligodendroglioma
11. Brain Cancer Diagnostics Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Brain Cancer Diagnostics Market, by End User
12.1. Introduction
12.2. Diagnostic Laboratories
12.3. Hospitals
12.4. Research Institutes
13. Americas Brain Cancer Diagnostics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Brain Cancer Diagnostics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Brain Cancer Diagnostics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. General Electric Company
16.3.2. Siemens Healthineers AG
16.3.3. Koninklijke Philips N.V.
16.3.4. Canon Medical Systems Corporation
16.3.5. F. Hoffmann-La Roche Ltd.
16.3.6. Thermo Fisher Scientific Inc.
16.3.7. QIAGEN N.V.
16.3.8. Illumina, Inc.
16.3.9. Abbott Laboratories
16.3.10. Agilent Technologies, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BRAIN CANCER DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. BRAIN CANCER DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRAIN CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRAIN CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PROBES & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY LAB INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TRAINING & SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 71. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 73. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 74. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 75. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 77. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 78. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 79. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. CANADA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 140. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 142. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 145. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 146. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. GERMANY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 156. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 157. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. FRANCE BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 173. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 174. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 175. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 177. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 178. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 179. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. ITALY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 183. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 184. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 186. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 188. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 189. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 190. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SPAIN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 233. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 234. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. DENMARK BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 250. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 251. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 252. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 253. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 254. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 255. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 256. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. QATAR BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 260. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 261. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 262. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 263. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 264. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 265. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 266. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 267. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 268. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. FINLAND BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 293. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 294. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 295. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 296. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 297. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 298. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 299. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 300. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 301. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. EGYPT BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 304. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 305. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 306. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 307. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 308. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 309. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 310. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 311. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 312. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. TURKEY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 314. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 315. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 316. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 317. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 318. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 319. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, 2018-2030 (USD MILLION)
TABLE 320. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
TABLE 321. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 322. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 323. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. ISRAEL BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 325. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 326. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 327. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 328. NORWAY BRAIN CANCER DIAGNOSTICS MARKET SIZE, BY PATHOLOGY, 2018-2030 (USD MILLION)
TABLE 329. NORWAY BRAIN CANCER DIAGNOS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Brain Cancer Diagnostics market report include:
  • General Electric Company
  • Siemens Healthineers AG
  • Koninklijke Philips N.V.
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.15 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Brain Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Brain Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Cancer Diagnostics Patent Landscape Report and Forecast 2024-2032 - Product Image

Cancer Diagnostics Patent Landscape Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
AI In Cancer Diagnostics Market Size, Share & Trends Analysis Report By Component (Software Solutions, Hardware, Services), By Cancer Type, By End-use (Hospitals, Surgical Centers and Medical Institutes), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

AI In Cancer Diagnostics Market Size, Share & Trends Analysis Report By Component (Software Solutions, Hardware, Services), By Cancer Type, By End-use (Hospitals, Surgical Centers and Medical Institutes), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Head & Neck Cancer Diagnostics Market by Product Type, Technology, End User, Application, Cancer Type - Global Forecast to 2030 - Product Image

Head & Neck Cancer Diagnostics Market by Product Type, Technology, End User, Application, Cancer Type - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
AI in Cancer Diagnostics Market Report 2025 - Product Image

AI in Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Brain Cancer Diagnostics Market

In the realm of medical diagnostics, the Brain Cancer Diagnostics market is a specialized segment focused on the identification and characterization of brain tumors. Diagnostics for brain cancer are critical for formulating effective treatment plans, as the nature and progression of brain tumors can vary greatly. The market includes various diagnostic modalities such as imaging techniques, biopsy procedures, and molecular and genetic tests. Imaging tests such as MRI and CT scans are often the first step in diagnosing brain cancer, providing detailed images of the brain to detect abnormalities. Biopsies, wherein tissue samples are extracted from the suspected cancerous region, provide definitive diagnosis. Advanced methods to analyze tissue samples include histopathological examination, immunohistochemistry, and molecular testing, which can give insight into specific genetic mutations and markers that may influence treatment strategies. As medical technology advances, the introduction of new diagnostic tools and methods continues to evolve the field. With the integration of artificial intelligence and machine learning, there is a growing potential for improved diagnosis accuracy and personalized treatment approaches. Some notable companies operating in the Brain Cancer Diagnostics market include GE Healthcare, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation, and Agilent Technologies. These organizations are involved in the production of imaging equipment, development of molecular diagnostics, and provision of services essential for the accurate diagnosis and management of brain cancers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.